Skip to search formSkip to main contentSkip to account menu

24 HR rivastigmine 0.192 MG/HR Transdermal System [Exelon]

Known as: Exelon 4.6 MG per 24HR 1 Day Transdermal Patch, RIVASTIGMINE 4.6 mg in 24 [USP'U] TRANSDERMAL PATCH, EXTENDED RELEASE [Exelon], 24 HR Exelon 0.192 MG/HR Transdermal System 
National Institutes of Health

Related topics

Related topics

5 relations

Broader (1)

24 HR rivastigmine 0.192 MG/HR Transdermal System
ExelonTransdermal Systemalpha Tocopherolrivastigmine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Optimization and characterization of rivastigmine nanolipid carrier loaded transdermal patches for the treatment of dementia.
Review
2016
Review
2016
Current Pharmaceutical Design
Worldwide, the percentage of people aged over 60 years is growing up quicker than any other age group, as a result of both longer… 
2013
2013
The impact of Medicare prescription drug coverage on the use of antidementia drugs
BackgroundCholinesterase inhibitors and memantine are prescribed to slow the progression dementia. Although the efficacy of these… 
2010
2010
Drug therapies for cognitive impairment and dementia.
Drugs currently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease include… 
Highly Cited
2010
Highly Cited
2010
Effects of Donepezil,Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer’s Disease
AbstractBackground: Acetylcholinesterase inhibitors (AChEIs) have been used to improve cognitive status and disability in… 
2007
2007
The cost-utility of Exelon ® patch in the management of patients with Alzheimer's disease in the UK
decline of AD patients. Social support and assistance with activities of daily living form the mainstay of nonpharmacological… 
2006
2006
Voltammetric Behaviour of Rivastigmine Hydrogen Tartrate and its Determination in Capsule Dosage Form
Rivastigmin hidrojen tartarat’in RVT elektrokimyasal davranisi camsi karbon elektrot kullanilarak diferansiyel puls voltametrisi… 
2004
2004
Memantine : A New Treatment Option for Patients with Moderate-to-Severe Alzheimer ’ s Disease
Alzheimer’s disease (AD) affects approximately 15 million people worldwide and more than four million Americans in the U.S. alone… 
2003
2003
Les inhibiteurs de l'acétylcholinestérase
Acetylcholinesterase inhibitor drugs. The approach to the treatment of Alzheimer's dementia has been greatly modified by the… 
Highly Cited
1998
Highly Cited
1998
The amnestic prodrome of Alzheimer's disease.
  • J. Hodges
  • Brain : a journal of neurology
  • 1998
  • Corpus ID: 44554630
The launch of two new drugs (Aricept® and Exelon®) for the treatment of Alzheimer’s disease heralds the end of an era of… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)